Mohamadreza Ahmadifard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohamadreza Ahmadifard has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Azin Khoshghiafeh
Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol 4774547176, Iran
4 shared publicationsMohammad Javad Kamali
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran
3 shared publications- Aida Hasanzadeh
Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol, Iran
1 shared publication Amirreza Mazloomi
Department of Medical Genetics, School of Medicine, Babol University of Medical Sciences, Babol 4774547176, Iran
1 shared publication- Cena Aram
Department of Cell & Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran
1 shared publication - Esmail Karami
Clinical Biomechanics and Ergonomics Research Center, Aja University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (4) , 101977
MYH9: Structure, functions, and therapeutic implications in cancer and genetic disorders
The myosin heavy chain 9 (MYH9) gene encodes non-muscle myosin heavy chain IIA (NMIIA), a vital protein involved in fundamental cellular activities, including movement, cell division, and signal transmission. Mutations in MYH9 were initially linked to autosomal dominant disorders collectively termed MYH9-related diseases (MYH9-RD). In recent years, MYH9 has gained significant attention for its pivotal roles in various cancers. However, despite extensive research, its exact contributions to cancer progression remain incompletely understood. Targeting MYH9 through approaches such as non-coding RNAs, small molecules, or gene therapy presents a promising avenue for advancing cancer treatment. Additionally, the dual role of MYH9 in MYH9-RD and cancer raises the intriguing question: are individuals with MYH9 mutations predisposed to or protected from cancer? This review aims to present the structure, functional significance, and clinical associations of MYH9, with an emphasis on its contributions to MYH9-RD and cancer progression. Furthermore, it examines MYH9’s regulatory interactions with non-coding RNAs and its potential applications as a therapeutic target, offering insights into strategies such as RNA interference and CRISPR-based gene editing for cancer treatment.
- 1 July 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (4) , 101977
Open AccessMYH9: Structure, functions, and therapeutic implications in cancer and genetic disorders
The myosin heavy chain 9 (MYH9) gene encodes non-muscle myosin heavy chain IIA (NMIIA), a vital protein involved in fundamental cellular activities, including movement, cell division, and signal transmission. Mutations in MYH9 were initially linked to autosomal dominant disorders collectively termed MYH9-related diseases (MYH9-RD). In recent years, MYH9 has gained significant attention for its pivotal roles in various cancers. However, despite extensive research, its exact contributions to cancer progression remain incompletely understood. Targeting MYH9 through approaches such as non-coding RNAs, small molecules, or gene therapy presents a promising avenue for advancing cancer treatment. Additionally, the dual role of MYH9 in MYH9-RD and cancer raises the intriguing question: are individuals with MYH9 mutations predisposed to or protected from cancer? This review aims to present the structure, functional significance, and clinical associations of MYH9, with an emphasis on its contributions to MYH9-RD and cancer progression. Furthermore, it examines MYH9’s regulatory interactions with non-coding RNAs and its potential applications as a therapeutic target, offering insights into strategies such as RNA interference and CRISPR-based gene editing for cancer treatment.
- 15 July 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt A) , 110771
Therapeutic targeting of triple-negative breast cancer: A multi-model evaluation of LNA-anti-miR-19b-3p and small molecule inhibitors
- 15 July 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt A) , 110771
Therapeutic targeting of triple-negative breast cancer: A multi-model evaluation of LNA-anti-miR-19b-3p and small molecule inhibitors
- 3 November 2023
- Published by Elsevier in Advances in Medical Sciences
- Vol. 68 (2) , 450-463
A comprehensive review of ACE2, ACE1, TMPRSS2 and IFITM3 gene polymorphisms and their effect on the severity of COVID-19
- 3 November 2023
- Published by Elsevier in Advances in Medical Sciences
- Vol. 68 (2) , 450-463
A comprehensive review of ACE2, ACE1, TMPRSS2 and IFITM3 gene polymorphisms and their effect on the severity of COVID-19
- 12 December 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 423 (1) , 113442
Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment
- 12 December 2022
- Published by Elsevier in Experimental Cell Research
- Vol. 423 (1) , 113442
Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment